Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Digip® raises €2 million led by Industrifonden to intensify geographical expansion

Stockholm, June 28, 2021. Digip® AB, a Swedish SaaS company in the legal tech industry that make trademark protection accessible, affordable, and functional, today announces a €2 million funding round led by Industrifonden. SeedX, Antler and angel investors also participated in the round. The funding will be used to grow the business and continue to fight trademark infringement on a global level.“Almost all business across the world is moving into the digital arena to some extent and as a result, the likelihood of encountering brand misuse is skyrocketing. In fact, 85 percent of all

Resolutions by Tele2’s Extraordinary General Meeting

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) today announced that the company’s Extraordinary General Meeting was held today on 28 June 2021. The Extraordinary General Meeting resolved on an extraordinary dividend to the company’s shareholders of SEK 3.00 per share, with the record date set to 30 June 2021.Due to the extraordinary situation as a result of the COVID-19 pandemic, the Extraordinary General Meeting was carried out through advance voting, without any physical attendance. The Extraordinary General Meeting resolved, in accordance with the Board’s

Historic US First as ABS, Robert Allan, Signet and USCG Use Purely 3D Process to Deliver Commercial Vessel

Paperless Process Delivers Time and Cost Savings Without Compromising Safety(HOUSTON) The first commercial U.S. vessel designed, built and verified using an end-to-end 3D design process is now under construction in a pioneering project by ABS, Robert Allan Ltd. (RAL), Signet Maritime Corporation (Signet) and the United States Coast Guard (USCG). Designed by RAL, the Advanced Rotortug® (ART), which is designed to escort vessels and offshore assets at the Port of Corpus Christi, will receive its Certificate of Inspection from the USCG and will now be built and operated by Signet to ABS

Getinge announces its Q2 Report 2021 on July 16 at 08:00 CEST followed by a conference call at 10:00 CEST

Getinge will issue its Q2 Report 2021 on July 16, 2021, at 08:00 CEST, followed by a conference call at 10:00 CEST, hosted by Mattias Perjos, President & CEO, and Lars Sandström, CFO.Fund managers, analysts and media are invited to participate in the conference call. Please see dial in details below to join the conference: SE: +46850558365UK: +443333009268US: +16319131422 During the conference call a presentation will be held. To access the presentation through webcast, please use this link: https://tv.streamfabriken.com/getinge-q2-2021  Alternatively, use the following link to

Urban transformation of Kiruna, Sweden: Caverion ensures optimal conditions for the new swimming hall

Caverion Corporation Investor news 28 June at 2021 at 10.00 a.m. EESTUrban transformation of Kiruna, Sweden: Caverion ensures optimal conditions for the new swimming hall We Group is creating a new, modern swimming hall with the latest technology for the municipality of Kiruna, Northern Sweden. Caverion has been selected as a partner for the delivery of the technical solutions needed to ensure optimal conditions for the swimming hall, including ventilation, energy center, heating and sanitation and water purification. The swimming hall is designed and projected by We Group,

Invitation to presentation of Bulten’s Q2 report 2021

Bulten’s half-year report for the period January – June 2021 will be published on Tuesday 13 July 2021 at 08:30 CET.A presentation for analysts, media and investors will be held the same day at 11:00 CET. The report will be presented by President and CEO Anders Nyström and CFO Anna Åkerblad via audicast. The presentation will be held in English and can be followed live via the link: https://tv.streamfabriken.com/bulten-q2-2021. It will also be possible to take part of the audiocast afterwards at the same address or at www.bulten.com/ir . To

Initiator Pharma receives CTA approval for Phase 2b study with IPED2015 in Erectile Dysfunction patients

Initiator Pharma A/S, a clinical-stage life science company, announced today that it has received final approvals for the Clinical Trial Application (CTA) for its planned Phase 2b study in Erectile Dysfunction patients with IPED2015 from both the Medicines & Healthcare products Regulatory Agency, MHRA, UK and the Ethics Committee. The patient recruitment is expected to start at end of July. The study will be carried out in collaboration with MAC Clinical Research, UK, at multiple centers across UK.“IPED2015 is our most advanced ED candidate with potential to become a new treatment method

Veg of Lund’s plant-based drink DUG enters coffee shops in Oxford, England

Oxford in England is renowned for its university, beautiful architecture and Harry Potter backdrop. But to make tourists and students feel at ease, a well-functioning environment with good coffee shops and tea stores is needed. Now, several of the most visited coffee shops have decided to supplement their range with DUG[®], the plant-based drink from Veg of Lund.“At last, we can see that England is opening up for more social contact. Since a couple of days, DUG[®], our potato-based drink, is available at several coffee shops in Oxford. Cafes that throughout history have meant a lot to

Acquisitions Update

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL This announcement does not constitute an offering circular, prospectus or other offer documents. No one should purchase or subscribe for any securities in TROPHY GAMES Development A/S ("TROPHY GAMES" or the "Company") except on the basis of information in the company description published by the Company in connection with the offering and admission of such securities

BioStock: Elicera receives ATMP classification from EMA

Last week, Elicera Therapeutics announced it has received Advanced Therapy Medicinal Products classification for its lead candidate ELC-100, an oncolytic virus that is currently undergoing a phase I/II trial for the treatment of neuroendocrine tumours. The classification is designed to get promising new cell or gene therapies to market faster, so it gives ELC-100 a welcome regulatory boost.Read the full article at biostock.se: https://www.biostock.se/en/elicera-receives-atmp-classification-from-ema/This is a press release from BioStock - Connecting Innovation & Capital.https://www.

Share subscriptions based on stock options 2016A

CapMan Plc Stock Exchange Release      28 June 2021 at 9:30 a.m. EET Share subscriptions based on stock options 2016A Between 16 April 2021 and 30 April 2021, a total of 14,350 CapMan Plc new shares have been subscribed for with the company's stock options 2016A. The entire subscription price of EUR 7,462.00 shall be recorded into the invested non-restricted equity fund. As a result of the subscriptions, the number of CapMan shares increases to 156,617,293. The shares subscribed for under the stock options have been registered in the Trade Register on 28 June 2021, as of which

Estimated time plan for execution of upcoming preferential rights issue in Initiator Pharma A/S

As previously communicated, Initiator Pharma A/S (“Initiator Pharma” or “the Company”) intends to carry out a preferential rights issue of a total of approximately SEK 29.4 million (before issue costs), which has been agreed in advance in writing through subscription and guarantee commitments to 100 percent. The Company's prospectus is for review by Finanstilsynet Danmark and the Company hereby communicates an estimated time plan for the implementation of the preferential rights issue. The terms of the issue, which have previously been decided and communicated through a press release, are

DBP International AB: a new patent for SA-033 is granted in USA

Double Bond Pharmaceutical's second patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in the United States. Patent approval provides protection for the treatment method and the design of composition for DBP's front-line product SA-033."We are very pleased because it is an important milestone in the development of balanced product pipeline", - comments Igor Lokot, CEO of DBP.More about SA-033: SA-033 is the first drug candidate that DBP has developed using its innovative

Altor acquires a majority stake in Palette Software

Altor Fund V (“Altor”) has signed an agreement to acquire a majority stake in Palette Software AB (“Palette”). Altor acquires the company from previous owner Monterro, founders and management. The ambition is to accelerate investments in growing Palette into one of the leading accounts payable automation software providers globally.Palette is an Accounts Payable automation (AP Automation) software company offering procure-to-pay and digital invoice processing solutions for the SME and mid-market segments. The company, which has 12o employees and is headquartered in Stockholm, has more than

Storytel and The Conan Doyle Estate in exclusive agreement – bestselling author Anthony Horowitz creates new adventures with Sherlock Holmes for Storytel Original

Sherlock Holmes is ready for new intriguing and mind-boggling adventures going audio first. An exclusive agreement between Storytel and The Conan Doyle Estate gives Storytel the privilege of developing completely new stories featuring the world’s most iconic and loved detective. The adventures will be written by a team of writers under the creative lead of award winning novelist and screenwriter Anthony Horowitz.“The Conan Doyle Estate’s curiosity and interest in our idea of taking the Sherlock Holmes legacy to a new place in a new digital format is a dream come true, and so is getting

Alfa Laval to supply complete process lines to one of the world’s largest olive oil mills

Alfa Laval has won an order to supply complete process lines to one of the world’s largest olive oil mills, which is to be built in Spain. Once completed in 2022 the mill will process about 180 million kilos of olives per season.The order comprises several complete process lines, including Alfa Laval high speed separators and decanters. In addition to being one of the world’s largest mills, it will also be one of the most sustainable and innovative facilities. It will run and evaluate Alfa Laval’s latest products within olive oil processing: the Alfa Laval Olive Oil Booster which

Azelio initiates collaboration with US-based MMR Constructors for joint energy storage projects

A Memorandum of Understanding (MoU) is signed between Azelio and MMR Constructors (MMR) with the intention to develop projects combining Azelio’s long-duration energy storage, TES.POD[®], with solar PV to supply customer with renewable energy around-the-clock. The collaboration aims at an installed capacity of 250 MWh of Azelio’s TES.POD[®] by 2027, starting with a small scale installation in 2022.MMR is an industry leader in instrumentation and electrical construction, maintenance, and technical services, based in the US and with a global footprint of projects completed in 36 countries. In

Forxiga recommended in EU for patients with CKD

28 June 2021 07:05 BST Forxiga recommended for approval in the EU by CHMPfor the treatment of patients with chronic kidney disease If approved, Forxiga has the potential to change the treatment paradigmfor millions of people in the EU suffering from chronic kidney disease AstraZeneca's Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive

Nirsevimab PhII/III trial confirms safety profile

28 June 2021 07:00 BST Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safetyand tolerability profile in infants at high risk of RSV Nirsevimab is being developed as a passive immunisation against RSV for all infants The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.[1] The trial assessed the safety of nirsevimab in infants with chronic lung disease (CLD), congenital heart disease (CHD) and/or

Embracer Group AB secures an unsecured multicurrency revolving credit facility of SEK 6.0 billion

Embracer Group AB secures an unsecured multicurrency revolving credit facility of SEK 6.0 billion arranged by leading Nordic banks Nordea, SEB and Swedbank. The facility has a tenor of three years which may be extended by up to two years and refinances in total SEK 4.4 billion in facilities with Nordea maturing in July, 2021 and May, 2022.The terms and conditions for the new facility has been improved, including a lower credit margin for utilized debt. The existing relationships with about a dozen international banks on operating group level will be maintained in addition to the facility.

YIT and NREP have agreed on the implementation of rental housing projects in Poland valued at nearly EUR 100 million

YIT Corporation Investor News 28 June 2021 at 09:00 a.m.YIT and NREP, the leading real estate investor and developer in the Nordic countries, have agreed on the construction of rental housing projects in Poland. The agreement concerns just over 1,000 apartments and its value is approximately EUR 100 million. The agreement will be added to the order book for the third quarter of 2021.  “Our strategic objective is to accelerate the development of multi-phase area projects by implementing some of the project phases as rental housing projects in cooperation with institutional investors.

Skanska invests about SEK 540M in a logistics facility in Helsingborg, Sweden

Skanska invests about SEK 540M in a logistics facility in Helsingborg, Sweden, which is fully let to Greenfood. The construction contract is worth about SEK 400M, which will be included in the Swedish order bookings for the second quarter 2021.Långeberga is a strategic logistics location in Helsingborg, just adjacent to the E4 / E6 / E20 junction that connects Copenhagen with Oslo and Stockholm. The 44,000-square meter facility will have a strong environmental focus in everything from material selection to efficient cooling systems and modern heat recovery. In addition, a solar cell system

Invitation to Electrolux Professional AB Q2 2021 presentation

Electrolux Professional AB will publish the Q2 2021 interim report for the period April – June 2021, on Thursday, July 22, at 08:00 CET.A telephone conference will be held at 09:00 CET with Alberto Zanata, CEO and Fabio Zarpellon, CFO presenting the result, followed by a Q&A session. The presentation will be available on https://www.electroluxprofessional.com/corporate/.Please use the following dial-in details to participate in the telephone conference: Sweden: +46 8 519 993 83 United Kingdom: +44 333 300 9274 United States: +1 631 913 1422 PIN: 71597406# Please note the pin

Telephone conference 16 July in connection with Interim report

The Interim report January-June 2021 will be released on Friday 16 July around 07.00 CEST.At 09.00 CEST a telephone conference will be held, participant connection: UK: +44 333 300 9032, SE: +46 8 566 426 92, US: +1 631 913 1422 PIN for US: 61959798#. The telephone conference will be webcasted live at www.ratos.com where presentation material will be available as soon as the report is released. The telephone conference will be recorded and available at www.ratos.com. For further information, please contact:Jonas Ågrup, CFO+46 70 626 01 83jonas.agrup@ratos.com About Ratos:

There are no items matching the current filter
There are no more items matching the current filter
Back to top